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Abstract
Background: Insulin-dependent Type 1 diabetes (T1D) is a devastating autoimmune disease that destroys beta cells within
the pancreatic islets and afflicts over 10 million people worldwide. These patients face life-long risks for blindness,
cardiovascular and renal diseases, and complications of insulin treatment. New therapies that protect islets from
autoimmune destruction and allow continuing insulin production are needed. Increasing evidence regarding the
pathomechanism of T1D indicates that islets are destroyed by the relentless attack by autoreactive immune cells evolving
from an aberrant action of the innate, in addition to adaptive, immune system that produces islet-toxic cytokines,
chemokines, and other effectors of islet inflammation. We tested the hypothesis that targeting nuclear import of stress-
responsive transcription factors evoked by agonist-stimulated innate and adaptive immunity receptors would protect islets
from autoimmune destruction.
Principal Findings: Here we show that a first-in-class inhibitor of nuclear import, cSN50 peptide, affords in vivo islet
protection following a 2-day course of intense treatment in NOD mice, which resulted in a diabetes-free state for one year
without apparent toxicity. This nuclear import inhibitor precipitously reduces the accumulation of islet-destructive
autoreactive lymphocytes while enhancing activation-induced cell death of T and B lymphocytes derived from autoimmune
diabetes-prone, non-obese diabetic (NOD) mice that develop T1D. Moreover, in this widely used model of human T1D we
noted attenuation of pro-inflammatory cytokine and chemokine production in immune cells.
Conclusions: These results indicate that a novel form of immunotherapy that targets nuclear import can arrest
inflammation-driven destruction of insulin-producing beta cells at the site of autoimmune attack within pancreatic islets
during the progression of T1D.
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Introduction
Type 1 diabetes (T1D) results from the progressive destruction
of insulin-producing beta cells in pancreatic islets caused by pro-
inflammatory and pro-apoptotic effectors of innate and adaptive
immunity. Extraordinary advances with insulin monotherapy and
understanding of the critical role of the adaptive immune system in
the T1D pathomechanism have not translated to diabetes reversal.
Patients remain at risk for the serious complications inherent to the
autoimmune and metabolic derangements in T1D. Given the side
effects of insulin therapy and current immunosuppressive
regimens, the search for new therapeutic approaches continues
[1]. The requisite roles of islet-specific autoreactive T and B cells
have been well established and have been the primary target of
current clinical investigations [2,3,4,5]. Building on the role of
adaptive immunity, both T cell-directed immunotherapy with
anti-CD3 and the B cell-directed action of rituximab (anti-CD20)
have shown similar efficacy in delaying the progression of new-
onset diabetes [2,6]. Unfortunately, while clinical benefit to
patients in these trials has been recorded[7], insulin-secreting
capacity continues to decline in treated individuals and these
regimens have not restored stable tolerance to islet tissue, perhaps
because they do not completely target the islet-destructive
autoimmune inflammatory process.
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13235A growing body of evidence now suggests that the innate
immune system, which is antigen non-specific and tightly coupled
to acute and chronic inflammation, plays an equally important
role in diabetes progression in genetically-predisposed individuals
and may also be amenable to therapeutic intervention
[8,9,10,11,12]. Clinically, the presence of chronic inflammation
is suggested by the persistent elevation in C-reactive protein and
also in the propensity of individuals with T1D to develop
accelerated atherosclerosis, which is now viewed as an inflamma-
tory disorder, irrespective of glycemic control [13,14]. Mechanis-
tically, the key role of innate immunity has been further supported
by the recent report that genetic ablation of the key adaptor of
innate immunity, MyD88, affords protection from T1D in specific
pathogen-free NOD mice [15]. Indeed, this study documented
that MyD88 signaling is critical for development of T1D; thus,
MyD88-dependent activation of innate immune cells by non-
tolerogenic constituents of the intestinal microbiome may be an
initiating event in the development of insulitis, the inflammatory
hallmark of T1D [16,17].
With respect to Type 1 diabetes progression, pro-inflammatory
signaling initiated through stimulation of the principal receptors of
innate immunity—Toll-like receptors (TLRs)—is one mechanism
that activates antigen-presenting cells (APCs). In turn, these
effectors of innate immunity render effector T cells resistant to
regulatory T cell (Treg)-mediated suppression [18,19]. As a
consequence, loss of peripheral tolerance ensues. This loss is
consistent with reports that naı ¨ve T cells in NOD mice are
resistant to Treg action [20,21]. Given their escape from both
peripheral and central selection processes, autoreactive T and B
cells go on to produce critical pro-inflammatory cytokines TNF-a,
IL-1b, and IFN-c that can lead directly to beta cell programmed
cell death (apoptosis) [22].
Production of these islet-toxic cytokines depends on tightly-
regulated intracellular signal transduction by stress-responsive
transcription factors (SRTFs), such as NF-kB, AP-1, NF-AT,
STAT-1, and others. NF-kB is the paradigmatic SRTF and is
well-known for its role in diabetes pathogenesis with crucial roles
played at the levels of both lymphocytes and beta cells [23,24,25].
However, other SRTFs, including NF-AT, AP-1, and STAT-1,
have also been implicated [26,27,28] by activating numerous
target genes that encode mediators of inflammation and apoptosis,
which underlie destruction of islets and other target tissues. These
positive effectors of pro-inflammatory immune signaling to the
nucleus participate in an auto-stimulatory loop, which amplifies
the inflammatory process initiated by microbial and autoimmune
triggers. Thus, uncontrolled nuclear translocation of SRTFs
represents an additional feature of the dysregulated immunity of
the murine model of Type 1 diabetes that may disrupt peripheral
tolerance [29,30,31,32,33].
To carry out these potential diabetogenic functions, activated
SRTFs are ferried to the nucleus of cells responding to innate and
adaptive immune stimulation. This culminating step in TLR-
evoked innate immunity and TCR-evoked adaptive immunity is
mediated by nuclear import adaptors known as importins/
karyopherins [34]. Thus, targeting these cytoplasmic adaptors with
an inhibitor of nuclear import offers a new level of control toward
dysregulated innate and adaptive immune signaling in T1D.
Inthisreport,wepresentevidencefora newmodeofT1Dcontrol
that allows simultaneous inhibition of TLR-evoked innate immunity
and TCR-initiated adaptive immunity. Since both immune
responses depend on intracellular signal transduction by stress
responsive transcription factors, we targeted the nuclear import
mechanism with a first-in-class, cell-penetrating nuclear import
inhibitor. We found that short-term intracellular delivery of this
inhibitor afforded long-term protection of the islets from inflamma-
tion-driven apoptosis. This long-lasting (one year) islet-protecting
effect, which arrests diabetes progression without the need for insulin
therapy, appears to involve the precipitous reduction of autoreactive
lymphocytes through enhancement of activation-induced cell death
of T and B lymphocytes. Moreover, this salutary effect of short-term
nuclear import targeting is associated with reprogramming of the
pro-inflammatoryandanti-inflammatorycytokineprofileofimmune
cells isolated from NOD mice.
Results
Primary lymphocytes and macrophages from NOD mice
are susceptible to attenuation of T cell receptor (TCR)-
and Toll-like receptor (TLR)-evoked pro-inflammatory
signaling by a nuclear import inhibitor
NOD mice, a widely used model of human T1D, demonstrate
genetic predisposition toward autoimmune diabetes as evidenced
by numerous immunologic abnormalities of innate and adaptive
immunity as compared to normal strains of mice [12,15,30,31,35].
We had previously demonstrated that nuclear import inhibitor,
cSN50 peptide, attenuates TCR- and TLR-evoked cytokine/
chemokine production in murine models of acute inflammation
and apoptosis using normal C57BL/6 and BALB/c strains
[36,37,38,39]. Therefore, we first examined whether agonist-
stimulated T and B lymphocytes and macrophages derived from
autoimmune diabetes-prone NOD mice are suppressed by
targeting nuclear import with cell-penetrating cSN50 peptide
(Fig. 1). Accordingly, we stimulated isolated NOD splenocytes
with the T cell agonists anti-CD3/CD28 or concanavalin A (Con
A) in the presence or absence of the nuclear import inhibitory
peptide cSN50 and measured the production of the pro-apoptotic
cytokine IFN-c. cSN50 suppressed the robust production of this
islet-toxic cytokine. Furthermore, we assessed the effect of cSN50
on B cells and bone marrow-derived macrophages (BMDM)
prepared from NOD mice and stimulated with the pro-
inflammatory agonist LPS that is recognized by Toll-like receptor
(TLR) 4 on macrophages and B cells. As NOD-derived B
lymphocytes are hyper-responsive to LPS in terms of CD80 (B7.1)
expression [35], we demonstrated that this response is attenuated
by cSN50. Moreover, expression of islet-toxic cytokines TNF-a,
IL-1a, and IL-1b in BMDM obtained from NOD mice was
suppressed. Thus, a nuclear import inhibitor attenuates produc-
tion of islet-toxic, pro-apoptotic mediators evoked by TCR and
TLR agonists in primary immune cells derived from NOD mice.
Intracellular delivery of a nuclear import inhibitor to the
pancreas reduces islet inflammation (insulitis)
The highly effective suppression of pro-inflammatory and pro-
apoptotic cytokines in ex vivo analysis of primary, NOD-derived
immune cells following treatment with cSN50 peptide encouraged
us to embark on in vivo study of Type 1 diabetes in NOD mice. We
first determined whether cSN50 would be delivered to the
pancreas, the primary site of autoimmune attack against beta
cells in pancreatic islets. We have demonstrated previously that
this cell-penetrating nuclear import inhibitory peptide is delivered
to blood leukocytes/lymphocytes, spleen, liver, and lung to
suppress acute liver and lung inflammation [36,38,40]. Using
confocal microscopy, we assessed the pancreatic delivery of FITC-
labeled cSN50 peptide following a single intraperitoneal (i.p.)
injection. Rapid and uniform intracellular delivery of FITC-
cSN50 was apparent throughout the pancreas within 2 h after
injection (Fig. 2A).
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on the ongoing insulitis. We selected the well-characterized
accelerated model of autoimmune diabetes in the NOD mouse
following a single bolus of cyclophosphamide (Cy), which
synchronizes progression of T1D. In this widely used animal
model of human Type 1 diabetes, two to four days following Cy
injection a peak pro-inflammatory cytokine response is reported,
which is followed by development of overt autoimmune diabetes in
2–4 weeks [41,42,43,44]. Therefore, we challenged 10-week old
female NOD mice with Cy in two groups of seven. We initiated
treatment with cSN50 or control (either a non-cell penetrating
peptide denoted cN50 or saline) 45 h later. To assure a steady
level of nuclear import inhibitor in blood and pancreas (see
Fig. 2A), we adopted a high intensity treatment protocol by
administering 35 mg/g of cSN50 i.p. every two hours for the next
24 h; mice receiving control peptide received a molar equivalent.
We analyzed pancreatic sections by immunohistochemistry
(Fig. 2B–D). Strikingly, 57% of treated mice following one-day
therapy with cSN50 were free of insulitis while significant insulitis
remained in all age-matched controls receiving Cy alone (p,0.05
vs treated). Our control finding compares well with other reports
of insulitis at this age which find nearly 100% of NOD mice to
demonstrate insulitis affecting a significant number of pancreatic
islets [45]. Islets from both groups of animals were assigned
insulitis scores based on the severity of inflammation (Fig. 2E).
Comparison of control to cSN50- treated animals shows
significantly more unaffected islets in cSN50-treated mice
(p,0.05) and significantly fewer severely affected islets
(p,0.001). Mean insulitis score was also determined and showed
a value of 0.49 in the cSN50-treated group and 1.81 in the control
group (p=0.001, Mann-Whitney U test). One year after the short-
course treatment, three treated mice were also analyzed
histologically. All three of these animals continued to show no
signs of insulitis (Fig. 2F). Thus, a short-term intracellular delivery
of cSN50 to the pancreas is followed by a rapid reversal of ongoing
insulitis that is otherwise exacerbated in untreated NOD mice
when T1D is synchronized with Cy.
Islet-reactive T cells are reduced and activation-induced
cell death (AICD) is enhanced by intracellular delivery of a
nuclear import inhibitor
Ongoing insulitis, as a hallmark of T1D in NOD mice, is driven
in part by the persistence of activated, autoreactive T and B
lymphocytes. They are resistant to activation induced cell death
Figure 1. Nuclear import inhibitor suppresses both T Cell Receptor- and Toll-Like Receptor-evoked signaling. Splenocytes from 10
week old NOD females were isolated and stimulated with anti-CD3/CD28 (2 mg/ml), concanavalin (1 mg/ml) (conA), or LPS (5 mg/ml) in the presence
or absence of nuclear import inhibitor (cSN50 peptide at 30 mM). Supernatants were harvested at 72 h and analyzed for presence of (A) IFNc as a
measure of T cell activation using cytokine bead array (**p,0.01 vs cSN50, t-test) and (B), Up-regulation of CD80 (B7.1) as a measure of B cell
responsiveness was assessed by flow cytometry (**p,0.01, Student’s t-test) on cells co-expressing CD19 as a B cell marker. (C) Pro-inflammatory
cytokine production in bone marrow derived-macrophages cultured in L-conditioned media. Differentiated cells were stimulated with LPS (10 ng/ml)
in the presence or absence of cSN50 (30 mM). cSN50 inhibited production of TNF-a, IL-1a, and IL-1b (*p,0.05, Student’s t-test). Data is representative
of three or more experiments.
doi:10.1371/journal.pone.0013235.g001
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tolerance [30,31,32,33]. Having observed elimination of T- and B-
lymphocytes in the islets of cSN50-treated NOD mice (Fig. 2B
and 2C), we hypothesized that intracellularly delivered cSN50
may enhance lymphocyte sensitivity to AICD, thereby reversing
the known resistance of NOD lymphocytes to this process
[30,32,33]. Although we had not observed changes in total
lymphocyte numbers above the transient cell loss following Cy
exposure (data not shown), we considered that autoreactive cells
may have been depleted following intense short-term treatment
with the nuclear import inhibitor. Therefore, we utilized adoptive
transfer of islet-reactive BDC2.5 lymphocytes to test their
persistence and expansion in pancreatic lymph nodes during
treatment with the nuclear import inhibitor. Donor cells were
labeled with CFSE and transferred to recipients that received
cSN50 or saline continuously via osmotic pump for 4 days (Fig. 3).
Analysis of the pancreatic lymph node demonstrated a striking
reduction in transferred islet-reactive cells in the cSN50- treated
mice, as demonstrated by a significant decrease in the absolute
number of CFSE-labeled, Vb4+ cells recovered at the end of
treatment. Islet-reactive BDC2.5 lymphocytes were precipitously
reduced following cSN50) peptide treatment either by an effect on
Figure 2. In vivo intracellular delivery of a nuclear import inhibitor to the pancreas attenuates insulitis. (A) cSN50 was conjugated to
FITC per the manufacturer’s instruction. Animals received one i.p. injection of FITC-cSN50 or an amount of FITC of equivalent relative fluorescence.
Animals were euthanized after 2 h and 10 mm frozen sections were cut and assessed by confocal microscopy. The cSN50-FITC peptide is distributed
throughout the pancreas. In contrast, FITC alone did not penetrate the organ and only the autofluorescent tissue border is seen. Pancreas is shown at
40x magnification. (B–D) cSN50 therapy attenuates ongoing insulitis. 10 week-old NOD females received one injection of Cy (0.2 mg/g). 45 h after
this injection, treatment was begun with cSN50 (35 mg/g every two hours) and continued for 24 h at which time the seven animals in each group
(treatment and control) were euthanized and pancreata obtained. Sections were stained for (B) CD3-PE (red) and (C) B220 (green). The differential
interference contrast (DIC or Nomarski) image is shown in panel (D). Of 7 animals assessed in each group, four NOD mice receiving cSN50 were
completely insulitis free as compared to persistent insulitis in all control group animals (p,0.05, chi-square). (E) All NOD mice receiving histologic
evaluation in cSN50-treated and control groups (n=7 for each) were assigned insulitis scores based on the severity of inflammation (0=no invading
cells, 1=peri-insulits, 2=invasive insulitis, 3=minimal residual islet tissue). Comparison of control to cSN50- treated animals shows significantly more
unaffected islets in treated mice (*p,0.05) and significantly fewer severely affected islets (**p,0.001). (F) Three animals were assessed at 1 year
follow-up for insulin production and insulitis. Sections were stained with a combination of anti-insulin FITC (green) and a combination of anti-CD3
and anti-B220PE (red). In long-term survivors (right), insulin staining is detected but insulitis was not observed. As a staining control, islets from 15
week old control NODs show significant insulitis.
doi:10.1371/journal.pone.0013235.g002
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node. We directly assessed the effect of the nuclear import
inhibitor on cell survival and proliferation by analyzing the
sensitivity of NOD lymphocytes to AICD in an ex vivo assay.
Splenocytes were harvested from 10 week old NOD females and
stimulated with a defined concentration of anti-CD3/CD28 for
65 h in the presence or absence of cSN50 before detection of
apoptosis with annexin-V staining (Fig. 4A). Importantly, we
focused on the detection of apoptosis in NOD lymphocytes with
definitive evidence of activation as determined by the achievement
of at least one cell division. Use of CFSE to calculate the number
of mitotic events following anti-CD3/CD28 stimulation revealed
that cSN50 had no effect on CD4 or CD8 T cell proliferation
(Fig. 4B). In contrast, intracellular delivery of cSN50 increased
the sensitivity to AICD in CD3/CD28-stimulated CD4+ and
CD8+ T cells (Fig. 4C). As anticipated, CD4 T cells from NOD
mice were generally more resistant to AICD but following cSN50
peptide delivery, they displayed a significant increase in sensitivity
to AICD; in fact, the percentage of CD4 T cells undergoing AICD
reached values comparable to T cells obtained from the non-
diabetes prone C57BL/6 strain (Fig. 5A). In parallel to the
significant change in sensitivity to AICD noted in NOD mice-
derived T cells, B lymphocytes also had an increase in sensitivity to
apoptosis induced by their agonist in the presence of cSN50
peptide. When B cells were analyzed with similar methods
following stimulation with the TLR4 agonist, LPS, they displayed
enhanced propensity for cell death (Fig. 5B). Thus, the nuclear
import inhibitor not only reduced the number of islet-reactive T
cells but restored sensitivity to AICD in T and B lymphocytes
isolated from NOD mice.
Immunomodulatory Cytokines IL-5 and IL-10 are
enhanced in animals treated with a nuclear import
inhibitor
Although cSN50 treatment eliminated the majority of islet-
reactive lymphocytes and facilitated reduction of insulitis, these
islet-reactive and invading immune cells did not completely vanish
following intense 1- or 4- day delivery of cSN50 peptide via ip
injection or osmotic pump, respectively. Therefore, we considered
whether there had been augmentation in regulatory cells or
whether the remaining lymphocytes demonstrate alteration in
their cytokine expression profile. Analysis of the absolute number
of regulatory T cells was determined by intracellular Foxp3
staining and showed no difference between treated and control
mice at either the end of treatment (48 h) or two weeks after
treatment concluded. With respect to cytokine expression, the
systemic effect of cSN50 on cytokines/chemokine production in
blood of NOD mice was monitored daily in plasma samples in
treated and control mice beginning on the day of Cy administra-
tion until 12 days following peptide treatment (day 14 post- Cy
bolus). During this period of administration, we detected increased
circulating levels of IL-5 on day 2 after Cy administration (Fig 6a).
Figure 3. Autoreactive T cells disappear following in vivo treatment with a nuclear import inhibitor. Twenty million CFSE- labeled
BDC2.5 splenocytes were transferred to pre-diabetic NOD recipients who received cSN50 peptide or saline by osmotic pump. On day 4 post-transfer,
pancreatic lymph node cells were harvested and the proliferation profile of CD4+Thy1.1- cells and absolute number of CFSE+ Vb4+ cells within the
CD4 compartment was determined. Treated mice showed significant reduction in the absolute number of recovered Vb4+ cells (*p,0.05, student’s t-
test). Figures are representative of three separate experiments.
doi:10.1371/journal.pone.0013235.g003
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IL-10, IL-12, IL-2, or IL-4, Eotaxin, GM-CSF, IL-1a, IL-1b,M -
CSF, IL-3, IL-7, IL-9, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-
17, IP-10, MIP-2, KC, LIF, LIX, MIP-1a, MIP-1b, MIG,
RANTES, or VEGF (data not shown) and most of these markers
of inflammation were barely detectable in plasma or were below
the limit of detection. However, we still considered that the
capacity for production of anti-inflammatory cytokines may have
been modified although increased systemic production of anti-
inflammatory cytokines, such as IL-10, was not detected.
Therefore, we obtained splenocytes from NOD females that had
received 24-h peptide therapy beginning two days after Cy
acceleration to examine the effect of cSN50 peptide on ex vivo
cytokine production by immune cells. Restimulated splenocytes
from treated animals showed increased production of the anti-
inflammatory cytokine IL-10 suggesting that cSN50 peptide was
not simply a global suppressant of pro-inflammatory cytokine/
chemokine production in NOD mice but rather a modulator of
lymphocyte function in lymphoid organs (Figure 6b). Together
with results depicted in Figure 1, these cumulative data indicate
the ability of a nuclear import inhibitor to exert a bimodal effect
on primary NOD immune cells by suppressing the expression of
pro-inflammatory mediators, including islet-toxic cytokines like
IFN-c and TNF-a while preserving or enhancing anti-inflamma-
tory cytokines such as IL-10.
Short-term treatment with nuclear import inhibitor
prevents accelerated T1D in NOD mice during a one-year
observation
Having established a striking effect of in vivo delivery of cSN50
peptide on reversal of insulitis through reduction of islet-reactive T
and B cells, we embarked on a pre-clinical study of cSN50 peptide
in terms of its effect on T1D progression. As above, we
synchronized T1D development in 10-week old female NOD
mice by a single bolus of Cy. After 45 h, we used a high intensity
treatment protocol by administering 35 mg/g of cSN50 i.p. every
two hours for the next 48 h to assure a steady level of nuclear
Figure 4. Activation-induced cell death (AICD) is enhanced following ex vivo intracellular delivery of a nuclear import inhibitor to
splenocytes.Splenocytes from10week-oldNODfemales were labeledwith CFSE andstimulated with anti-CD3(0.05 mg/mlor 2 mg/ml)andanti-CD28
(1 mg/ml) in the presence or absence of cSN50 (30 mM). After 65 h of culture, samples were harvested and labeled with annexin V-PE, anti-CD8 PerCP,
and anti-CD4 APC. For analysis of AICD, activation was defined as the achievement of at least one round of division as determined by CFSE-dilution; a
representative gating strategy is shown in (A); the undivided peak is highlighted in green and derived from unstimulated cells in the same experiment.
(B) The CFSE division history, represented graphically as the number of mitoses per 10,000 CD4 or CD8 T cells, demonstrated no change in proliferation
in CD4 or CD8 T cells in the presence of cSN50 (p=NS). (C) Further analysis revealed increased annexin-V staining on activated cells, indicative of cellular
apoptosis, for cSN50-treated CD4 and CD8 T cells (p,0.005, paired student’s t-test). Data is representative of at least 4 separate experiments.
doi:10.1371/journal.pone.0013235.g004
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saline or control peptide at molar equivalent. As documented in
Fig. 7, the majority of NOD mice (90%) were rendered diabetes-
free following this short-term treatment of only 2 days with cSN50.
In contrast, 90% of control mice developed diabetes by 100 days
after Cy bolus. The progression to diabetes in control group
proceeded in two phases. On days 10–30, a first wave of diabetes
developed and cSN50 afforded 100% protection against this
process. In the second wave, corresponding closely to the normal
progression of spontaneous diabetes between days 60–100 post-Cy
(ages 18–23 weeks), protection was incomplete but still substantial
even though more than two months had elapsed since the last dose
of nuclear import inhibitor. Strikingly, the cSN50 peptide-treated
mice remained euglycemic, which obviated the need for insulin
replacement therapy. Importantly, they did not display overt signs
of toxicity during 365 days of observation. The lack of toxicity of
intensive treatment in this model was supported by normal weight
gain, no signs of acquired infection, and normal clinical
chemistries (ALT and BUN levels were not significantly different
from control, Fig. 8). Moreover, we did not detect anti-cSN50
peptide antibody induction in an ELISA assay where the limit of
detection based on a titration of cSN50-reactive IgG antibody was
10 ng/mL (O.D. values for serum were not significantly different
from secondary antibody alone).
Thus, short-term targeting of the nuclear import of stress-
responsive transcription factors with cSN50 peptide suppressed
accelerated autoimmune diabetes progression and rendered
thriving NODmicefree ofdiabetesprogression forat leastone year.
Discussion
The ultimately fatal outcome of autoimmune diabetes in the
widely used and clinically relevant murine NOD model of human
T1D depends on progressive and relentless destruction of insulin-
Figure 5. cSN50 restores Activation-Induced Cell Death
(apoptosis) in NOD CD4 T cells and enhances B cell apoptosis
in response to LPS. Splenocytes from 10-week-old NOD or C57BL/6
female mice were isolated and stimulated with anti-CD3/28 (2 mg/ml) or
5 mg/ml LPS in the presence or absence of cSN50 (30 mM). After 70 h
culture, cells were harvested and apoptosis was detected by annexin V
PE staining with lymphocyte co-labeling with either anti-CD4 APC (A)o r
anti-CD19 APC (B). (A) NOD splenocytes when stimulated with anti-
CD3/28 showed reduced apoptosis as compared to C57BL/6 spleno-
cytes as previously published (*p,0.01, t-test). Addition of cSN50
normalized apoptosis to C57BL/6 levels (p=NS). Unstimulated lympho-
cytes showed high levels of apoptosis, as expected for unactivated
lymphocytes in culture; this process was not enhanced by cSN50. (B)
Exposure to cSN50 significantly enhanced sensitivity to cell death in
LPS-stimulated B lymphocytes (p,0.005, paired Student’s t-test).
doi:10.1371/journal.pone.0013235.g005
Figure 6. Expression of immunomodulatory cytokines IL-5 and
IL-10 is modified during treatment with a nuclear import
inhibitor. (A) Blood samples were obtained daily by saphenous vein
bleeding beginning on the day of Cy challenge. Cytokine levels in
plasma were determined by cytokine bead array and comparison to a
standard curve. cSN50-treated mice demonstrate increased IL-5
(p,0.05 ANOVA; subsequent analysis of individual days by Student’s
t-test shows *p,0.05 for days 2 and 3) during therapy. (B) Splenocytes
from 10 week-old NOD females that had received cyclophosphamide
were harvested after 24 hr of treatment with cSN50 or control non-cell-
penetrating peptide (cN50) and restimulated with LPS to assess their
cytokine profile. Supernatants were harvested at 72 h and analyzed by
cytokine bead array for presence of IL-10. Splenocytes from cSN50
treated animals produced increased levels IL-10 (*p,0.05). Data are
from three separate experiments.
doi:10.1371/journal.pone.0013235.g006
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insulin-replacement therapy is instituted. We investigated the
possibility of protecting islets from autoimmune attack by
intracellular delivery of a nuclear import inhibitory peptide
(cSN50). Our results indicate that cSN50 effectively protected
islets from immune destruction. This protection is vested in
significant reduction of islet-reactive T cells, restoration of the
sensitivity of T and B cells to AICD, suppression of islet-toxic pro-
inflammatory cytokine production in primary T and B cells and
macrophages isolated from NOD mice, and preservation of a key
anti-inflammatory cytokine, IL-10. Thus, a nuclear import
inhibitor extinguished autoimmune inflammation-driven islet loss
and prevented further progression of diabetes thereby obviating
the need for insulin replacement therapy.
Remarkably, none of the cSN50 peptide-treated animals
developed hyperglycemia during the first phase of diabetes onset
occurring between days 10–30 after receiving a bolus of cyclophos-
phamide (Cy), which synchronizedthe autoimmunediabetesprocess
in NOD mice. In addition to this early protective effect, cSN50
treatment also afforded significant long-term islet protection. While
another half of Cy-synchronized control animals progressed to
diabetes between days 50 and 100, only two of twenty cSN50-
treated animals developed diabetes, a finding suggesting that cSN50
treatment resulted in long-term islet protection in NOD mice that
are genetically-prone to T1D. This favorable outcome is supported
by our demonstration of in vivo elimination of islet-infiltrating and
islet-reactive lymphocytes (Fig. 3), most likely through enhanced
AICD, which was demonstrated ex vivo in cSN50 peptide-treated T
and B cells (Fig. 4). Our data indicate that at higher levels of
stimulation (e.g., higher concentrations of the mitogenic stimulus,
anti-CD3), thesensitivitytoAICD isfurtherincreasedbythe nuclear
import inhibitory peptide. Thus, chronic activation of islet-
infiltrating T and B cells in autoimmune diabetes may favor the
AICD-enhancing effect of the nuclear import inhibitor.
This hitherto unreported action of cSN50 in a relevant
preclinical T1D model adds autoimmune inflammation to the list
of conditions in which a nuclear import inhibitor has displayed
therapeutic utility. We have previously demonstrated the efficacy
of nuclear import inhibitor delivery and its anti-inflammatory and
cytoprotective action in acute inflammation models, including
lethal challenge with superantigen, staphylococcal enterotoxin B
(SEB), and lipopolysaccharide (LPS), which trigger acute inflam-
matory lung and liver injury [40,46]. Moreover, we have
documented inhibition of nuclear entry of stress-responsive
transcription factors, NF-kB, NF-AT, AP-1, and STAT-1 in
human T lymphocytes [37]. Of relevance to autoimmune diabetes
is the documented role of these transactivators in lymphocyte
activation and beta cell apoptosis [22,24,47,48,49]. Moreover,
nuclear import of Nrf2, a critical responder to oxidant stress, is
also attenuated by SN50 peptide [50].
An important aspect of our nuclear import inhibitor is its ability
to reach the pancreas (Fig. 2A) and cells comprising pancreatic
Figure 7. Short-term intracellular delivery of a nuclear import inhibitor in vivo protects NOD mice from autoimmune diabetes for
over one year. Ten week old female NOD mice received one dose of Cy (0.2 mg/g) to synchronize autoimmune diabetes progression. After 45 h,
intracellular peptide delivery was initiated with cSN50 (35 mg/g) or with control and continued every 2 h for 48 h. Blood glucose was assessed twice
weekly. cSN50-treated mice (n=20) were significantly protected from diabetes progression as compared to saline-treated control (n=10, p,0.0001)
or the non-cell-penetrating peptide cN50-treated control (n=10, p=0.006). A comparison of cSN50- treated vs. the combined control groups as
illustrated in the figure also demonstrated significant protection (p=0.0002, log-rank test).
doi:10.1371/journal.pone.0013235.g007
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We have previously elucidated the mechanism of intracellular
delivery of this peptide and documented an endocytosis-indepen-
dent process of crossing the plasma membrane mediated by the
membrane-translocating motif (MTM), which is based on the
signal sequence hydrophobic region (SSHR) derived from Kaposi
FGF [51]. The amphipatic helix-based structure of SSHR
facilitates its insertion directly into plasma membrane and the
tilted transmembrane orientation permits the translocation of the
nuclear import inhibitor through the phospholipid bilayer of the
plasma membrane directly to the interior of the cell without
perturbing membrane integrity [52]. This mechanism explains the
efficient delivery of SSHR-guided cargo across the plasma
membrane of multiple cell types involved in autoimmune
inflammation.
Overall, our study presents a new avenue for altering the course
of diabetes progression as there has been limited success in
obviating the need for parenteral insulin-replacement therapy of
T1D to date. Recent advances in immunosuppressive/anti-
inflammatory therapy using monoclonal antibodies that target T
cells, B cells and cytokine receptors have produced encouraging
results. These efforts have focused on targeting extracellular
receptors on T and B cells without discerning islet-destructive
autoreactive T and B cells from primary innate immunity cells
[2,6]. The latter encompass monocytes, macrophages, and
dendritic cells that contribute not only to islet inflammation and
apoptosis but also to the loss of peripheral tolerance to beta cells
antigens. Consistent with their role in autoimmune inflammation,
they are being also controlled by nuclear import inhibition. Hence,
a broad repertoire of SRTFs-regulated genes that encode
mediators of islet inflammation and beta cells apoptosis is
attenuated. Contributing to the short-circuiting of this pro-
inflammatory signaling cascade, nuclear import inhibition re-
versed resistance of autoreactive T cells to Activation-Induced Cell
Death (AICD). Indeed, as islet-reactive lymphocytes are likely to
be maximally stimulated during disease progression, cSN50
enhanced their deletion as compared to those lymphocytes
without islet-reactive specificities (cf. Figs 2,3,5). Thus, cSN50
treatment seems to restore peripheral T and B cell tolerance,
which critically depends on the appropriate regulation of
lymphocyte AICD [53].
In addition to enhancing autoreactive lymphocyte elimination,
the nuclear import inhibitor may also modulate the cytokine
milieu established by immune cells in their target organs. We
found that cSN50 inhibits pro-inflammatory cytokine expression
in ex vivo analyzed NOD splenocytes while preserving and even
modestly enhancing the anti-inflammatory cytokine IL-10. We
have previously observed a similar enhancement of IL-10 in other
models of acute inflammation that were ameliorated by nuclear
import targeting. Moreover, we have also found an increase in IL-
5 in the plasma of treated mice during the first day of cSN50
therapy. We did not find increased levels of IL-4 or IL-13 and thus
it is unclear whether this increased IL-5 is indicative of a shift
towards a Th2 phenotype. While Th2 shifts have occasionally
been associated with diabetes protection, it is not clear that this
shift is a part of the true protective mechanism in many cases [54].
Significantly, the pattern of increased IL-10 and IL-5 was also seen
in human subjects in the original trial of anti-CD3 [2].
Cumulatively, these findings suggest that IL-10 and IL-5 may
play an important role in modulating the course of Type 1
diabetes in tolerized individuals.
Our results with a nuclear import inhibitor suggest that
reduction or complete elimination of islet-destructive autoreactive
T cells may be useful in treating T1D and potentially other
autoimmune diseases. Under conditions of metabolic, inflamma-
tory, and oxidant stress, beta cell mass may be further controlled
by important interactions between bone marrow-derived cells and
islet beta cells [55]. Transcriptional modulation of these
interactions via targeting of the nuclear import machinery
represents an important new opportunity for therapeutic devel-
opment. We are aware that the ability of cSN50 to block nuclear
transport of several stress-responsive transcription factors that
utilize importin/karyopherin alpha 1 for nuclear trafficking
[37,50] raises concern regarding potential side effects of this novel
approach. However, intracellular delivery of the nuclear import
inhibitor is rapid and restricted to the relatively short half life of
the injected cargo [37]. Nonetheless, whether this therapy would
be tolerated during longer-term application, if necessary, to
prevent or reverse spontaneous disease remains an important
Figure 8. Short-term treatment of NOD mice with a nuclear
import inhibitor shows no effect on measured clinical bio-
markers of liver and kidney toxicity. Ten week old female NOD
mice received one dose of Cy (0.2 mg/g); after 45 h, intracellular
peptide delivery was initiated with cSN50 (35 mg/g) or with control
cN50 and continued every 2 h for 48 h. Serum was obtained daily from
the saphenous vein and measurements of ALT and BUN were
performed in 7 mice in each group. No significant differences were
determined. Measurements for alkaline phosphatase, creatinine, crea-
tine kinase, and total bilirubin were below the limit of detection in both
groups.
doi:10.1371/journal.pone.0013235.g008
Nuclear Import Drives T1D
PLoS ONE | www.plosone.org 9 October 2010 | Volume 5 | Issue 10 | e13235consideration. It is thus reassuring that despite high intensity
dosing of cSN50 in our current protocol, we did not observe short-
term or long-term adverse effects. In other disease models, we have
continued cSN50 peptide delivery for up to 8 weeks without
evidence of toxicity including normal animal health and survival,
normal weight gain, normal liver enzymes, and absence of
apparent infectious illness.
In summary, this report provides the first, to our knowledge,
evidence to document that short-term intensive targeting of the
nuclear import shuttle for stress-responsive transcription factors
can protect islets from relentless autoimmune attack and induce
long-term remission of T1D in NOD mice with established
insulitis. The evidence presented here that chronic inflammatory
destruction of beta cells could be reversed without overt signs of
toxicity should engender further preclinical studies of this novel
form of intracellular immunotherapy in T1D.
Materials and Methods
Mice and Diabetes Monitoring
NOD/LtJ, NOD-BDC2.5 and C57BL/6 mice were purchased
from the Jackson Laboratories (Bar Harbor, ME) at 6–8 weeks of
age. All mice were housed and maintained according to the
guidelines for use and care of laboratory animals as set forth by
VanderbiltUniversity and regulated via the Vanderbilt IACUC. All
NOD mice were monitored twice weekly for the development of
diabetes by blood glucose measurement with FreeStyle FastTake
test strips (Abbott Laboratories, Abbott Park, IL). Two consecutive
glucose measurements .220 mg/dl constituted a diagnosis of
diabetes. Although we did not maintain our own colony of NOD
mice, a colony kept by a collaborating laboratory (PLK) in the same
animal suite has a spontaneous diabetes incidence of 80–90% in
females by 30 weeks of age [56] indicating an animal environment
that is conducive for diabetes development.
Isolation of lymphoid cells and preparation of bone
marrow derived macrophages
Splenocytes and lymph node cells were prepared by dispersion
of the organ and passage through a 70-mm cell strainer followed by
red cell lysis and resuspension in the media of choice for the given
experiment. For preparation of primary macrophages, bone
marrow from pre-diabetic, 8–12 week old female NOD mice
was prepared by flushing mouse femurs and tibias with ice-cold
DMEM supplemented with L-glutamine. Bone marrow cells were
pooled, passed through a 25 5/8-gauge needle, and filtered
through a 70-mm cell strainer. Pooled cells (1610
6 cells/ml) were
suspended in DMEM supplemented with 10% FBS, 10 mM
HEPES, penicillin (100 U/ml), streptomycin (100 mg/ml), and
20% L929 conditioned medium followed by plating on 150-mm
bacterial Petri dishes. Cells were incubated at 37uC in 5% CO2 in
humid air. Every 3 days, non-adherent cells were removed, cells
were washed, and culture medium was replaced. Cells were used
in experiments after 10 days of culture for up to 2 weeks after
maturation. When analyzed by flow cytometry, 95% of the
adherent cells were MAC3+, CD3–, and B220–. The viability of
BMDMs was .80% before use in all experiments.
Ex vivo stimulation of NOD lymphocytes
Cells were plated in 24-well plates at a density of 1610
6
total cells/ml in DMEM containing 10% HI-FCS, penicillin
(100 U/ml), streptomycin (100 mg/ml), 2-mercaptoethanol
(55 mM), and varying amounts of the identified stimulus including
anti-CD3 (0–2 mg/ml) with 1 mg/ml anti-CD28, LPS (5 mg/ml),
or concanavalin A (1 mg/ml) (conA). All cells were incubated for
65–70 h at 37uC in 5% CO2.
Synthesis, purification, and labeling of a cell-penetrating
peptide inhibitor of nuclear import (cSN50) and its non-
cell-penetrating control (cN50)
Cell-penetrating peptide (cSN50, MW=3149), and non-cell-
penetrating peptide (cN50, MW=1651), were synthesized,
purified, filter-sterilized, and analyzed as described elsewhere
[37,38]. To monitor the intracellular delivery of peptides to
pancreas, cSN50 peptide was coupled with fluorescein isothiocy-
anate (FITC, Pierce) according to the manufacturer’s protocol, as
previously described [40].
In Vivo Intracellular Peptide Delivery to the Pancreas
For in vivo detection of fluorescein-labeled peptides in the
pancreas, NOD mice were sacrificed at 2 h after intraperitoneal
(IP) injection of 0.7 mg of FITC-labeled cSN50 peptide/mouse.
The pancreata were washed with saline and prepared for
cryosections (10 mm thickness). Control solution of FITC alone
with equivalent fluorescence units was injected separately to track
distribution to the pancreas.
Synchronization of T1D Progression with
Cyclophosphamide
At 10–11 weeks of age, female NOD mice received an
intraperitoneal bolus injection of 200 mg/kg cyclophosphamide
(Sigma). Cyclophosphamide was prepared by reconstitution of
powder in sterile saline for injection.
Treatment with Nuclear Import Inhibitor and Control
45 h after diabetes synchronization with cyclophosphamide,
treatment with cSN50 or control was initiated. Mice receiving
cSN50 were given 35 mg/g of cSN50 i.p. every two hours for the
next 48 h. Control mice received either saline or non-cell
penetrating cN50 peptide at molar equivalent (20 mg/g). All
injections were delivered in a volume of 100 ml of sterile saline
Immunohistochemistry
Freshly harvested pancreata were fixed in 4% paraformaldehyde-
0.1 M PBS (12.07 g of Na2HPO4 (dibasic), 2.04 g of KH2PO4
(monobasic), 8.0 g of NaCl, 2.0 g of KCl; pH 7.5, same-day
preparation) for 1.5 h at 4uC under mild agitation, followed by four
washings in 0.1 M PBS over a period of 2 h at 4uCu n d e rm i l d
agitation. Tissue was equilibrated in 30% sucrose in 1x PBS
(Invitrogen) overnight at 4uC until tissue settled to the bottom of
the tube. Pancreata were then frozen in OCT (Sakura Finetek), and
cut into 8 mm sections using a cryostat microtome (Leica). Sections
were rehydrated with PBS for 2 min before blocking for 30 min at
room temperature in blocking buffer (5% normal goat serum and 1%
BSA in 1x PBS),thenstained with anti-B220-FITCand anti-CD3PE
for 1 h at room temperature, washed with PBS, and mounted in
fluorescent mounting medium (Dako). Slides were examined by
conventional fluorescence microscopy using an Olympus BX60
epifluorescence microscope. Images were captured using a charge-
coupled device camera and MagnaFire software (Optronics) and
optimized for signal-to-noiseusing AdobePhotoshopsoftware (Adobe
Systems). A pancreas was deemed insulitis-free if at least 40 islets were
identified and no islet had evidence of T or B-cell staining.
Flow Cytometry
One million splenocytes were suspended in PBS containing
0.1% azide and 3% FCS and surface stained with the following
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B220), 53-6.7 (anti-CD8), or 16-10A1 (anti-CD80), each conju-
gated to FITC, PE, PE-Cy7, Cychrome or APC as appropriate.
Annexin V staining was performed in the appropriate binding
buffer as supplied. All reagents were obtained from BD
Pharmingen (San Jose, CA). All samples were analyzed on
FACSCalibur flow cytometer (Becton Dickinson, Mountain View,
CA) using CellQuest software.
CFSE Labeling
Spleens were harvested, and cells were labeled and prepared as
previously described [30]. Mitotic events were determined as
previously reported [30] based on the two-fold decrease in
fluorescence intensity with each division of labeled cells.
In vivo tracking of islet-reactive CD4 T cell elimination
during nuclear import inhibitor treatment
Splenocytes were isolated from NOD BDC2.5 TCR transgenic
mice and labeled with CFSE. A total of 20610
6 of these CFSE-
labeled cells was injected intraperitoneally into NOD-Thy1.1
mice. For BDC2.5 T cell transfers, optimal activation occurs at
about 90 h [57], and so recipient cells were harvested at this time
point from pancreatic lymph nodes. Single cell suspensions were
prepared and stained with anti-Thy-1.1 PE-Cy7 (OX-7), anti-
TCR Vb4-PE (the BDC2.5 transgene utilizes Vb4 TCR) and anti-
CD4 APC (RM4-5) to allow for the identification of the
transferred CD4 T cells using flow cytometry. To allow continuous
and facile peptide delivery throughout the 4-day incubation
period, mice were implanted with osmotic pumps the day prior to
cell transfer. Implantation was achieved following induction of
anesthesia with ketamine and xylazine per standard protocol and
the pump was placed into a subscapular location. The wound was
closed with a single staple. These 4-day pumps deliver 100 ul of
fluid at 1 ul/hr and generally begin infusion about 12 hrs after
implantation (Alzet, Cupertino, CA).
Cytokine detection by cytokine bead array
Serum or plasma samples were obtained daily by saphenous
vein bleeding. Other samples for cytokine determination were
obtained from supernatants of stimulated lymphocyte cultures.
Cytokine concentration was determined by cytokine bead array
and comparison to a standard curve (BD Biosciences, San Jose,
CA) or with the MILLIPLEX mouse cytokine-chemokine kit
(Millipore, St. Charles, MO) according to the manufacturer’s
specifications.
Clinical Chemistry
ALT and BUN levels were determined on a VITROS 250
Chemistry analyzer using multi-layered vitros slides and colori-
metric or enzyme rate tests as appropriate.
Statistical analysis
Statistical comparison between groups was performed by log-
rank analysis, Student’s t-test or ANOVA as appropriate. A p-
value less than 0.05 was considered significant.
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